Medicure Inc. · TSXV:MPH
Medicure — Investor Presentation (December 2021)
34 slides from Medicure's investor presentation, Dec 7, 2021
Slide 1: Investor Presentation
Medicure Inc. Investor Presentation December 7, 2021 MPH:TSXV
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-loo
Slide 3: Our Vision
WHERE WE ARE GOING Our Vision We want to be a leading cardiovascular pharmaceutical company in the U.S. We have a vertically integrated team, pipeline and acquisitions in place to build We want to be a leading provider of pharmaceutical growth. and healthcare products to U.S. customers We have a ver
Slide 4: What Sets Us Apart
What Sets Us Apart Our approach to engagement and service with healthcare professionals Focusing on value for hospitals, prescribers, and patients 4 MPH:TSXV
Slide 5: Medicure's Acquisition of Marley Drug Pharmacy: The Industry Game-Changer
Medicure’s Acquisition of Marley Drug Pharmacy: The Industry Game-Changer Slides 23-26 MPH:TSXV 5
Slide 6: Our Products and Pipeline
Our Products and Pipeline DEVELOPMENT REGULATORY APPROVED PRODUCT CATEGORY / CLINICAL APPROVAL / MARKETED AGGRASTAT® Hospital IV Injectable Branded antiplatelet, grew from 2% to 65% market share Prescription ZYPITAMAG® Branded statin with large market potential Consumer Sodium Hospital IV Injectable
Slide 7: Strategic Approach
Strategic Approach 1 Maintain positive earnings and cash flow 3 Acquisitions of synergistic companies or through existing products and innovation in cardio products for US market direct-to-consumer sales PROFITABILIY DEVELOPMENT ACQUISITION 2 Expand product offering through development of high margi
Slide 8: Net Revenue, EBITDA and R&D Investments
Net Revenue, EBITDA and R&D Investments Net Revenue Adjusted EBITDA R&D Investments $6.0 $1.5 $1.8 $1.6 $1.0 $5.0 $1.4 $0.5 $4.0 $1.2 $CAD (M) $0.0 $1.0 $3.0 -$0.5 $0.8 $2.0 $0.6 -$1.0 $0.4 $1.0 -$1.5 $0.2 $0.0 -$2.0 $0.0 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 Q3 Q4 Q1 Q2 Q3 2020 2021 2020 2021 2020 2021 MPH
Slide 9: Key Financial Information
Key Financial Information Capital Structure as of December 7, 2021 • Issued Shares 10,251,313 • Fully Diluted Total 11,073,913 • Share Price C$1.10 • Market Cap C$11.2M Financial Highlights • 2020 Net Revenue $11.6M • 2020 Adj. EBITDA ($3.9M) – investments in sales of 2 new products and R&D • Q3 202
Slide 10: The Story
The Story medicure’
Slide 11: Medicure Leadership Team
Medicure Leadership Team Albert D. Friesen, PhD Neil Owens, PhD David Gurvey, CPA, Reuben Saba, PhD Chief Executive Officer and President and CMA, B.Sc. Vice President, Chairman of the Board Chief Operating Officer Chief Financial Officer Medical and Business Affairs • Founded Medicure in • Joined M
Slide 12: Medicure's History and Trajectory
Medicure’s History and Trajectory 2024 Projected Launch of MC-1 NDA 2022 Projected Launch of Cardio ANDA 2021 Launch of Medicure’s E-Commerce Platform 2020 Acquisition of Marley Drug Pharmacy 2019 Acquisition of ZYPITAMAG, investment in Sensible Medical, launch of Sodium Nitroprusside, SIB returning
Slide 13: AGGRASTAT (tirofiban hydrochloride) Profile
AGGRASTAT® (tirofiban hydrochloride) Profile Estimated Patient Market Share Background: 100% (GP IIb/IIIa Inhibitors) • Hospital product (GP IIb/IIIa inhibitor) for acute cardiovascular care • US rights acquired in 2006 80% • High Dose Bolus (HDB) dosing approved in 2013 • New 15 mL bolus vial forma
Slide 14: AGGRASTAT Sales Update
AGGRASTAT Sales Update Aggrastat Net Revenue By Quarter Aggrastat Units Per Quarter Analysis ($ CAD Millions) 35,000 • Unit Demand in Q3 2021: $4.0 • 4% higher compared to Q2 2021 30,000 $3.5 • 9% higher compared to Q3 2020 25,000 $3.0 • Net Revenue in Q3 2021: 20,000 $2.5 • 4% higher compared to Q2
Slide 15: SAVI-PCI Study Met Its Primary Endpoint
SAVI-PCI Study Met Its Primary Endpoint Randomized clinical study evaluating AGGRASTAT (short and long infusions) compared to INTEGRILIN® (eptifibatide) These results fill a gap in clinical evidence and provide an exciting development to bolster the contemporary use of AGGRASTAT MPH:TSXV Please refe
Slide 16: Strategic Approach for AGGRASTAT
Strategic Approach for AGGRASTAT 1 Market use of LEVERAGE KOL AGGRASTAT through SUPPORT Key Opinion Leaders NEW CLINICAL 2 Market new clinical data from SAVI-PCI DATA MPH:TSXV 16
Slide 17: ZYPITAMAG (pitavastatin) Profile
ZYPITAMAG® (pitavastatin) Profile Key Information A New Type of Statin: • Lowers cholesterol, with some benefits over other statins • Metabolized differently from most other statins • Well tolerated with low rates of muscle pain 17 MPH:TSXV Please refer to IMPORTANT SAFETY INFORMATION on slide 34
Slide 18: ZYPITAMAG (pitavastatin) Profile
ZYPITAMAG® (pitavastatin) Profile Clinical Differentiation Target Patient Groups Zypitamag is different from most other statins (minimally Of 17 million Americans taking a statin, 5-10% have side effects processed by CYP enzymes) Direct competitor Livalo currently has 0.37% of the statin Reduced ris
Slide 19: ZYPITAMAG Sales Update
ZYPITAMAG Sales Update Zypitamag Net Revenue per Quarter Zypitamag Unit Demand per Quarter Analysis ($ CAD Thousands) • Unit Demand in Q3 2021: 350,000 $450 • 17% lower compared to Q2 2021 $400 • 3x higher compared to Q3 2020 300,000 $350 250,000 $300 • Net Revenue in Q3 2021: • 2% lower compared to
Slide 20: Marketing Focus
Marketing Focus 1 Simplicity in pricing ACCESSIBILITY without need for insurance, filled via Marley Drug 2 Metabolized differently DIFFERENTIATE from other statins and well tolerated MPH:TSXV 20
Slide 21: Customer Quotes
Customer Quotes “The best lipid levels I “ZYPITAMAG just have had in treating works for me. And, it's cholesterol... I have affordable” not had any side effects” “I personally tried multiple statins and “With ZYPITAMAG - had intolerable side my cholesterol levels effects. Because are down and I ZYPI
Slide 22: Strategic Approach
Strategic Approach 1 We have a talented sales team meeting with SALES TEAM healthcare providers to share the benefits and accessibility of ZYPITAMAG 2 Market the benefits CONSUMER of ZYPITAMAG and MARKETING how it is different from other statins MPH:TSXV 22
Slide 23: Marley Drug Pharmacy Subsidiary
Marley Drug Pharmacy Subsidiary • A US pharmacy located licensed to ship medications to all 50 states, Washington D.C. and Puerto Rico • Net Revenue in Q3 2021 of $1.64M • Thousands of existing customers and proven success in marketing based on pricing of generic drugs & focus on cash price without
Slide 24: Why Did Medicure Acquire Marley Drug
Why Did Medicure Acquire Marley Drug What this provides to Medicure 1. A more efficient distribution and marketing vehicle for ZYPITAMAG – a Branded drug 2. A marketing vehicle for other Branded drugs challenged to get insurance coverage 3. Saves on high fees to wholesalers and pharmacy benefit mana
Slide 25: Reasons Why Americans Pay Cash for Medications
Reasons Why Americans Pay Cash for Medications Factors Driving Americans to Pay Cash for Pharmaceuticals 1 2 3 4 5 High Not-Covered or Coverage Gap Deductibles Non-Preferred • More consumers are • High non-preferred • Medicare Part D enrolled in high co-pay ‘donut hole’ or deductible plans Under-Ins
Slide 26: E-Commerce Platform and Go Forward Plans
E-Commerce Platform and Go Forward Plans 1 Meet the demand of Americans who want to CONSUMER purchase medications online MARKETING with a seamless purchase experience 2 We are exploring BUSINESS opportunities that align DEVELOPMENT with our goals Marley Drug MPH:TSXV 26
Slide 27: Development of MC-1 for Rare Pediatric Disease
Development of MC-1 for Rare Pediatric Disease • PNPO deficiency is a rare pediatric disease, which leads to seizures and is fatal if untreated • The disease leads to the inability to produce a critical cofactor required for normal development • Currently there is orphan drug status, with no approve
Slide 28: New Cardio Products - Our Target Product Profile
New Cardio Products - Our Target Product Profile In-Hospital Value Urgent care IV products used in Cardio products that can be hospital = build on the licensed or acquired with low or experience, relationships and no initial investment, and if success of AGGRASTAT and licensed can be acquired with s
Slide 29: Investments and Returns to Shareholders
Investments and Returns to Shareholders APICORE (2014-2017) SENSIBLE MEDICAL (2019) SIB (2019) • July 2014 – Acquired 5% interest in • USD $10M investment in Sensible Medical • Completed substantial issuer bid (SIB) Apicore with a 3-year option to in 2019 for $26M in cash purchase the remaining shar
Slide 30: Q3 2021 Financial Results Summary
Q3 2021 Financial Results Summary $ millions CAD Q3 2021 Q2 2021 Q3 2020 Net Revenue 4.9 5.1 3.5 COGS 2.0 2.0 1.3 Selling Expenses 2.6 2.5 0.92 Net Income (loss) (0.95) (0.64) (1.0) FX Gain (loss) (0.22) (0.17) (0.21) Adjusted EBITDA 0.28 0.16 0.004 Context: Consistent revenue in Q3 2021 from Marley
Slide 31: Key Takeaways About Medicure
5 Key Takeaways About Medicure 1. Medicure’s focus is on pharmaceuticals and healthcare products for the US market 2. Proven success with AGGRASTAT, building sales of ZYPITAMAG 3. Focus on direct consumer sales for growth and profitability through Marley Drug subsidiary 4. Pipeline of products inclu
Slide 32: Further Information
Further Information Visit our Websites Investor Relations Medicure.com ir@medicure.com AggrastatHDB.com 1.888.435.2220 (Ext. 228) Zypitamag.com Marleydrug.com Follow us Contact a Product Specialist Linkedin.com/company/medicure 1.800.509.0544 Twitter.com/MedicureInc Instagram.com/medicureinc MPH:TSX
Slide 33: Important AGGRASTAT Safety Information
Important AGGRASTAT Safety Information Indication: AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Slide 34: Important ZYPITAMAG Safety Information
Important ZYPITAMAG Safety Information IMPORTANT SAFETY INFORMATION FOR ZYPITAMAG (pitavastatin) INDICATIONS & USAGE Drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addi